Mantenimiento a 4 años del aclaramiento completo con bimekizumab en 10 pacientes en España procedentes del estudio BE RADIANT A. López Ferrer; I. Belinchón Romero; R. Rivera Díaz; P. Herranz Pinto;

Safety and Efficacy Profile of Anti-IL17 Treatments in Hidradenitis Suppurativa: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials O. Al-wattar-Ceballos; L. Martínez-Montalvo; M. Carmona-Rodríguez;

[Translated article] Updated Perspective from the Spanish Psoriasis Working Group (GPS) on Biosimilar Drug Use in Moderate-to-Severe Psoriasis L. Salgado-Boquete; L. Puig; J.M. Carrascosa; P. de la Cueva; A. López Ferrer;